The European anchor: a royalty that grew while capital tightened
The clearest European data point in our material comes from Stockholm. BioArctic AB (Nasdaq Stockholm: BIOA B) reported that its partner Eisai recorded Leqembi sales of JPY 29.3 billion in the second quarter of 2026, which produced a royalty to BioArctic of SEK 179 million, about 10 percent more than the royalty for the second quarter of 2025.1 The headline understates the trend. Q2 2025 contained a one-time stockpiling effect in China of around JPY 5.3 billion, and BioArctic says that excluding it, royalty revenues in Q2 2026 grew approximately 43 percent year over year.1 In BioArctic's own words: "Excluding the stockpiling effect, royalty revenues in Q2 2026 grew approximately 43 percent compared to the same quarter last year."1
Both figures are the company's own, and the 43 percent depends on its adjustment for the stockpiling. We cannot check either against a filing. What the pair shows is a royalty model: a European company is paid on a partner's sales and carries none of the cost of selling the drug. That makes it a different kind of biotech from the cash-burning ones below.
The rest of the European picture is thin, and we say so rather than stretch it. The one other European item in the material is Idorsia's appointment of Begoña Carreño-Gómez as Chief Business Development Officer, effective November 1, 2026.2 That is a staffing change, not a result. The material contains no EU regulatory ruling, no EMA decision and no European funding data. This is therefore mostly a story about a global sector with a European royalty earner in it, not about European policy.
The backdrop: three signals of tighter money
On October 30, 2026 a $1 trillion tech selloff deepened fears of an AI bubble, with big AI bills and weak earnings spooking investors. The Nasdaq 100 had its worst day since June.3 The next day, OpenAI cut its funding target by $10 billion.4 On November 1, Binance users withdrew $3.6 billion when the exchange reopened after a hack.5
These events are not about biotech, and the material does not show any of them causing a specific biotech financing to fail. Our reading is that they describe a market in which investors are asking harder questions about spending ahead of revenue. That is the question every pre-revenue drug developer faces. This is Via News's interpretation, not a finding from the data.
What a cash cushion looks like: Incyte, from SEC filings
Incyte Corporation, a Wilmington, Delaware drug company that develops Jakafi, Opzelura and pemigatinib, is the one company in our material with fidelity-checked financials. Its cash was $3.98 billion in Q2 2026, from SEC filings.6 That is about four times the $987 million it held in Q2 2024.6 It then fell to $3.28 billion in Q3 2026.6 Cash was $3.46 billion in Q1 2026.6
The annual figures swing more than most readers would expect from a company of this size: $3.21 billion at FY 2023, $1.69 billion at FY 2024 and $3.10 billion at FY 2025.6 The filings give the level, not the reason. We have not seen the cause of the FY 2024 trough in this material, so we do not offer one.
The cost of producing what it sells has risen steadily: $255.0 million in FY 2023, $312.1 million in FY 2024 and $372.1 million in FY 2025.7 Quarterly, it rose from $76.6 million in Q2 2024 to $105.0 million in Q2 2026 and $108.7 million in Q3 2026.7 That is the pattern of a company with growing sales, though our material holds no revenue figures to confirm it. Earnings per share were $2.65 in FY 2023.7
One seam to flag: capital expenditure is recorded as exactly $48.7 million in both FY 2024 and FY 2025.8 Both values are marked canonical from SEC filings, but two identical annual figures are unusual enough that a careful reader should check the filings before relying on either. Incyte also licensed an asset to Dermavon Holdings Limited, according to our entity records. We have no terms, so we draw no conclusion about the deal.
The other end of the spectrum: runways and 2027 dates
The smaller companies in this story are pricing time, not profit. Scribe Therapeutics, now listed on Nasdaq under SCTX, says it raised capital to fund initial development of STX-1150, STX-1200 and STX-1400, and expects initial clinical data from STX-1150, its cholesterol-lowering gene silencing therapy, in the first half of 2027.9 It also expanded a collaboration with Sanofi.9 Scribe argues that current LDL-C therapies suffer from poor persistence, with studies showing 50% to 70% of patients stopping within a year.9 It also reports that people with naturally occurring PCSK9 loss-of-function variants have 28% lower mean LDL-C and up to 88% lower coronary heart disease risk.9 These are company claims in a results release, and the human trial has not yet produced data.
Vor Bio is further along, with the strongest clinical numbers in the dossier. Final two-year Phase 3 results for telitacicept in IgA nephropathy showed an annualized eGFR slope of -0.6 against -5.7 mL/min/1.73 m² per year for placebo, a difference of 5.1 (p<0.001), with 89% and 81% reductions in risk of confirmed 30% and 40% eGFR declines.10 eGFR is a standard measure of kidney filtering. These are the sponsor's reported results.
The others are earlier. Akari Therapeutics (Tampa and London) plans Phase 1 development of AKTX-101 in mid-2027 and describes ADC-refractory patients as "a significant, growing unmet need" and an exclusive opportunity for its novel payload.11 Ernexa said it remained on schedule to submit an IND for ERNA-101 in the third quarter of 2026, with a first-in-human trial in the fourth quarter.12 Prelude expected an IND for PRT13722 by mid-2026 and a Phase 1 start in ER-positive breast cancer in the second half of 2026.13 Both statements are forward guidance, and our material does not confirm that either milestone was met. OPKO reported that its candidate OPK8801001 showed roughly 20-fold greater growth hormone receptor antagonism than Pegvisomant, but only in vitro, in a test tube.14
AI-bio and the limits of the evidence
Radical Numerics says AI-designed viruses have treated its first patient, with an experimental treatment targeting drug-resistant E. coli.15 That is a company statement relayed by a newsletter, without trial data. Separately, Generation Lab claims its injection "blocks the systemic spread of aging in the bloodstream, reawakens the body's own repair mechanism and restores health and youth to multiple tissues."16 We include it as a claim, not a finding. Our measured reliability for the MIT Technology Review material in this dossier is low: 6% of 16 checked claims held up. The press releases are better but far from clean, at 54% of 6,692 checked claims. Treat all of the above as statements to verify, not conclusions.
What to watch
- Scribe's first STX-1150 human data, guided for the first half of 2027.9
- Akari's planned Phase 1 start in mid-2027.11
- Whether Ernexa and Prelude report the IND filings and trial starts they guided to for 2026.1213
- BioArctic's next quarterly royalty, to see whether growth holds once the China comparison is no longer distorted.1
- Incyte's cash against the $3.28 billion Q3 2026 level.6
One gap should be stated plainly: our material has no verified data on Eli Lilly's weight-loss drugs, so we make no claim about them.

